Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inmed Pharmaceuticals Inc (NQ: INM ) 0.2516 -0.0098 (-3.75%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Inmed Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 Next > TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Interim Chief Financial Officer, Changes Auditor December 13, 2022 Via Investor Brand Network InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor December 12, 2022 From InMed Pharmaceuticals Inc. Via GlobeNewswire CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding November 22, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding November 22, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market November 21, 2022 From InMed Pharmaceuticals Inc. Via GlobeNewswire CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding November 18, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding November 18, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market November 18, 2022 From InMed Pharmaceuticals Inc. Via GlobeNewswire TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Accounting VP, Controller November 17, 2022 Via Investor Brand Network InMed Provides Update on Management Changes November 17, 2022 From InMed Pharmaceuticals Inc. Via GlobeNewswire InMed Pharmaceuticals (NASDAQ: INM) Says Research Grant to Test Cannabinoid Analogs as a Potential Treatment for Alzheimer’s, Parkinson’s and Huntington’s Disease November 16, 2022 InMed Pharmaceuticals, Inc. (NASDAQ: INM) is a pharmaceutical research and development company that is focused on utilizing cannabinoids and related Via Spotlight Growth BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor November 16, 2022 Via Investor Brand Network InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding November 16, 2022 From InMed Pharmaceuticals Inc. Via GlobeNewswire TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2023 Financial Report, Corporate Update November 14, 2022 Via Investor Brand Network InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update November 11, 2022 From InMed Pharmaceuticals Inc. Via GlobeNewswire BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at ‘Exploring the Neuroprotective Qualities of Rare Cannabinoids’ Webinar Event November 10, 2022 Via Investor Brand Network Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022 November 10, 2022 Meet with InMed’s President and CEO Eric A. Adams and Eric Hsu, SVP of Preclinical Research and Development From InMed Pharmaceuticals Inc. Via GlobeNewswire BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Support of EB Awareness Week October 26, 2022 Via Investor Brand Network InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week October 26, 2022 From InMed Pharmaceuticals Inc. Via GlobeNewswire CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update September 23, 2022 Via Investor Brand Network CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update September 23, 2022 Via CannabisNewsWire BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Release FY 2022 Financial Report, Corporate Update September 20, 2022 Via Investor Brand Network TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $6M Private Placement Agreement September 14, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters into $6M Securities Purchase Agreement September 12, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property InMed Pharmaceuticals Inc. (NASDAQ: INM) Shares Record Huge Gains in Monday Morning Trading September 12, 2022 Via Investor Brand Network BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Update on Company Objectives and Programs September 09, 2022 Via Investor Brand Network BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Board Appointment, Changes August 09, 2022 Via Investor Brand Network BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on Phase 2 EB Trial July 25, 2022 Via Investor Brand Network BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Michael Woudenberg as Chief Operating Officer July 18, 2022 Via Investor Brand Network CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal June 14, 2022 Via Investor Brand Network < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.